LDN

Artykuły naukowe związane z NZJ (zawsze pamiętamy o podaniu autora i źródła kopiowanego materiału).

Moderatorzy: Anette28, Moderatorzy

Zablokowany
dzierzba
Początkujący ✽✽
Posty: 62
Rejestracja: 27 sty 2007, 12:05
Choroba: CD
Lokalizacja: w-wa
Kontakt:

LDN

Post autor: dzierzba » 28 lut 2007, 01:05

pogrzebalem na stronie overmed znalazlem ciekawe informacje o nowych badaniach nad czym co zostalo nazwao skrotowo LDN od niskich dawek naltrexonu lek ten stosowany jest przy uzaleznieniach od narkotykow i alkoholu ale tez przy stwardnieniu rozsianym :)) ale ponoc moze pomoc i nam jak pogrzebie wiecej to napisze co nieco narazie tylko tyle ze badania w polsce teraz prowadza w stanach ponizszy akrtykul
Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.

OBJECTIVES: Endogenous opioids and opioid antagonists have been shown to play a role in healing and repair of tissues. In an open-labeled pilot prospective trial, the safety and efficacy of low-dose naltrexone (LDN), an opioid antagonist, were tested in patients with active Crohn's disease. METHODS: Eligible subjects with histologically and endoscopically confirmed active Crohn's disease activity index (CDAI) score of 220-450 were enrolled in a study using 4.5 mg naltrexone/day. Infliximab was not allowed for a minimum of 8 wk prior to study initiation. Other therapy for Crohn's disease that was at a stable dose for 4 wk prior to enrollment was continued at the same doses. Patients completed the inflammatory bowel disease questionnaire (IBDQ) and the short-form (SF-36) quality of life surveys and CDAI scores were assessed pretreatment, every 4 wk on therapy and 4 wk after completion of the study drug. Drug was administered by mouth each evening for a 12-wk period. RESULTS: Seventeen patients with a mean CDAI score of 356 +/- 27 were enrolled. CDAI scores decreased significantly (P= 0.01) with LDN, and remained lower than baseline 4 wk after completing therapy. Eighty-nine percent of patients exhibited a response to therapy and 67% achieved a remission (P < 0.001). Improvement was recorded in both quality of life surveys with LDN compared with baseline. No laboratory abnormalities were noted. The most common side effect was sleep disturbances, occurring in seven patients. CONCLUSIONS: LDN therapy appears effective and safe in subjects with active Crohn's disease. Further studies are needed to explore the use of this compound. (Am J Gastroenterol 2007;102:1-9).

PMID: 17222320 [PubMed - as supplied by publisher]

wedleinfo ktore znalazlem to wszystko opiera sie na czymc co zostalo nazwane LP299V
tyle ze kwestia ile z tego co pisza jest prawda w polsce tez robili badania ne ten temat w 2001 w szczecinie u dzieci i ponoc byly bardzo obiecujace prowadzil to .. zgublem nazwisko :( znajde. Dziwne jest tylko to ze pomimo obiecujacych wynikow nic z tym wiecej nie zrobili. Bede szuakl dalej

Mamcia
Specjalista od Spraw medycznych
Posty: 10316
Rejestracja: 04 mar 2004, 16:08
Choroba: CD u dziecka
województwo: mazowieckie
Lokalizacja: Warszawa
Kontakt:

Re: LDN

Post autor: Mamcia » 28 lut 2007, 21:58

Przyłacz się do Towarzystwa J-elita. Działamy dla waszego dobra, ale bez Waszej pomocy niewiele zrobimy.

Zablokowany

Wróć do „NZJ - artykuły naukowe”